Genetic Engineering Symposium in Iowa City, Iowa

Vivek K Goyal vkgoyal at
Thu Mar 12 00:31:30 EST 1992

                      24TH ANNUAL TAU BETA PI SYMPOSIUM ON

                              Genetic Engineering:
                               Cures From Within
                Therapeutic Proteins-Roadway to the Marketplace

                            Thursday, March 19, 1992
                                2:30 - 5:40 p.m.
                     Triangle Ballroom, Iowa Memorial Union
                Campus of The University of Iowa, Iowa City, Iowa

Cosponsored by:
     Iowa Beta Chapter, Tau Beta Pi National Engineering Honor Society
     University of Iowa College of Engineering
     University of Iowa Graduate College
     University of Iowa Student Association

                               Schedule of Events

2:30  -   Introductory Remarks:
          Jeff Lussman, Tau Beta Pi Iowa Beta Chapter President;
          James W. Kaster, Moderator.

2:40  -   Dr. David W. Murhammer

3:00  -   Dr. Margaret H. Marino
          Research Specialist, Monsanto Company
          "Recombinant Protein Engineering and Potential Applications"

3:40  -   Break

3:45  -   Dr. John S. Logan
          Vice President of Research, DNX, Inc.
          "Production of Recombinant Proteins in Transgenic Animals"

4:25  -   Break

4:35  -   Dr. Kenneth B. Seamon
          Food and Drug Administration
          "Regulatory and Scientific Issues and the Evaluation of Biotechnology
          Derived Products"

5:15  -   Questions and Answers


Dr. Margaret H. Marino
"Recombinant Protein Engineering and Potential Applications"
(Editor's note:  Abstract was not available at press time.  The following is
Dr. Marino's informal description of her talk.)
I will discuss the steps a research scientist would take to express a
recombinant protein, what expression systems are available and how one chooses
an expression system, the obstacles one encounters in the production of
recombinant proteins, the importance of the polymerase chain reaction to
biotechnology and finally several specific examples which demonstrate the
potential applications of recombinant proteins.

John S. Logan
"Production of Recombinant Proteins in Transgenic Animals"
The current biotechnology industry uses single cell organisms (bacteria, yeast,
or mammalian cells) as production systems for recombinant human proteins such
as insulin, growth hormones, erythropoietin, etc.  Alternatively, it is now
possible using transgenic technology to produce these proteins in animals in
vivo.  A description of the basic methodology of this system will be presented.

It is possible that production of proteins in a transgenic system may offer
advantages over the more traditional biotechnological approaches since in some
cases, transgenics may be able to exactly reproduce or, more likely, better
approximate the precise structure of the desired protein.  This could also be
achieved at commercially relevant levels.  Examples of these proteins will be
discussed.  Moreover in the case of proteins such as human hemoglobin, which
will be used as a basic constituent of a blood substitute, that will be
required in large quantities, administered in large doses and manufactured for
a low cost the transgenic system may offer significant advantages over
traditional approaches.  The advantages of this system will be discussed.

Kenneth B. Seamon
"Regulatory and Scientific Issues and the Evaluation of Biotechnology Derived
Biotechnology has provided the means to produce therapeutic drugs and
biologicals previously obtainable only in small quantities.  In contrast to
conventional drugs which have been primarily small molecules produced by
organic synthesis, these therapeutic products are large molecules that are
produced in living organisms.  The use of living organisms to produce
therapeutic products raises concerns that are different from those for small
molecule drugs and are related to the technology which is used to produce the
product.  In addition, the complicated nature of biological products requires
that a combination of tests be applied in order to assess and guarantee their
safety, purity, and potency.  A framework for addressing many of these concerns
has evolved after years of experience in licensing vaccines and blood
components.  Many biotechnology derived products have been approved as
therapeutics and have been used safely, which attests to the success of
maintaining an active interaction between the industry and the regulatory
authorities in developing frameworks for evaluation of these products. 
However, new therapeutic strategies and diverse products will continue to be
developed and it is crucial that the regulatory process maintain the
flexibility to adapt to these new technologies.  The above issues will be
discussed as they relate to a variety of diverse therapeutic products.

The Speakers:

     Dr. Marino received her Ph. D. in 1983 from the Department of Biological
Chemistry of Pennsylvania State University with Dr. M. Miljkovic where her
thesis research involved the chemical synthesis of chiral macrocyclic ligands
from monosaccharide precursors.  Dr. Marino was a postdoctoral research
assistant with Dr. J. Hopper at the M. S. Hershey Medical Center, Hershey, PA
where she developed a gene cloning and integrative transformation system for
the hydrocarbon-metabolizing yeast, Yarrowia lipolytica.  In 1985 Dr. Marino
joined the Monsanto Company, St. Louis, MO where she has conducted research in
the expression of foreign proteins in yeast and also investigated a potential
drug delivery system based on microbial cell adhesion components.  Dr. Marino
is currently project leader for research directed towards the identification
and development of ion channel antagonists as potential antiarrhythmic or
immunosuppresant therapeutic agents.

     Dr. Logan joined DNX in June 1989 as Director, Molecular and Cellular
Biology Research, and assumed his current position in June 1991.  From February
1988 to June 1989, Dr. Logan was Group Leader of Molecular and Cellular Biology
at American Cyanamid Company, a pharmaceutical and biotechnology company, where
his primary responsibility was to establish programs for the development and
production of novel biopharmaceutical products.  From July 1985 to February
1988, he was a Research Scientist at American Cyanamid.  Dr. Logan received his
undergraduate and Ph. D. degrees in Biochemistry from the University of
Glasgow, in Scotland, U.K.  His postdoctoral fellowship at Princeton University
was under the direction of Dr. Thomas Shenk.  Dr. Logan is the author of
numerous scientific publications and patent applications.

     Dr. Seamon is chief of the Molecular Pharmacology Laboratory in the
Division of Biochemistry and Biophysics, Center for Biologics Evaluation and
Research, Food and Drug Administration and participates in the the review and
evaluation of biological products including therapeutic recombinant proteins,
monoclonal antibodies, and in-vitro diagnostic test kits.  Dr. Seamon directs
research programs in cellular regulation and has published extensively in the
area of signal transduction.  The Molecular Pharmacology Laboratory also serves
as a resource for the production and use of synthetic peptides, provides
assistance in the isolation and microsequencing of peptides and proteins, and
conducts basic research in the are of developmental biology.  He received his
B.A. in Chemistry from Washington University and his Ph. D. in Chemistry from
Carnegie Mellon University.  Dr. Seamon is a member of the Editorial board of
the Molecular Pharmacology and Section Editor for the Annual Reports in
Medicinal Chemistry.

The Moderator:

Mr. Kaster, Director of District II of Tau Beta Pi, has become the traditional
moderator of the annual "Symposium on Technology and its 

More information about the Bionews mailing list